West Virginia 2026 Session Status: Introduced 2 R cosponsors

HB 4640 — Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration

Last action — On 1st reading, House Calendar

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House of Delegates
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2026 Session. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.

Summary

Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration

Bill Text

What changed in the latest version

562 added · 1082 removed

Plain-language change summary

The latest version of Bill HB 4640 updates the authority of the West Virginia Board of Pharmacy to not only recommend substances for the state's controlled substance schedules during the legislative session but also to make emergency changes between sessions based on federal agency recommendations. Additionally, it removes a previous reference to specific organic psilocybin substances that could be scheduled. This change is significant because it broadens the Board's powers to react more swiftly to emerging drug issues and ensures that legislative procedures are more adaptable to federal guidelines.

→
Previous
Latest
WEST VIRGINIA LEGISLATURE REGULAR SESSION Introduced House Bill 4640 By Delegates Worrell and Hite [Introduced January 21, 2026;
WEST VIRGINIA LEGISLATURE REGULAR SESSION Committee Substitute for House Bill 4640 By Delegates Worrell and Hite [Introduced Committee on Health and Human Resources;
referred to the Committee on Health and Human Resources] Intr HB 2026R1161 A BILL to amend and reenact §60A-2-204 of the Code of West Virginia, 1931, as amended, relating to schedule I drugs;
Reported on January 27, 2026] CS for HB4640 Click here to enter text.
and adding a provision relating to the scheduling of an organic psilocybin substance or crystalline polymorph psilocybin approved by the Food and Drug Administration and the Drug Enforcement Administration.
A BILL amend and reenact §60A-2-201 and §60A-2-204 of the code of West Virginia, 1931, as amended, relating to schedule of drugs.
§60A-2-204.
§60A-2-201.
Authority of Board of Pharmacy;
recommendations to Legislature.
(a) The Board of Pharmacy shall administer the provisions of this chapter.
It shall also, on the first day of each regular legislative session, recommend to the Legislature which substances should be added to or deleted from the schedules of controlled substances contained in this article or reschedule therein.
The Board of Pharmacy shall also have the authority between regular legislative sessions, on an emergency basis, to add to or delete from the schedules of controlled substances contained in this article or reschedule such substances based upon the recommendations and approval of the federal food, drug and cosmetic agency, and shall report such actions on the first day of the regular legislative session immediately following said actions.
In making any such recommendation regarding a substance, the Board of Pharmacy shall consider the following factors:
(1) The actual or relative potential for abuse;
(2) The scientific evidence of its pharmacological effect, if known;
(3) The state of current scientific knowledge regarding the substance;
(4) The history and current pattern of abuse;
(5) The scope, duration and significance of abuse;
(6) The potential of the substance to produce psychic or physiological dependence liability;
and (7) Whether the substance is an immediate precursor of a substance already controlled under this article.
(b) After considering the factors enumerated in subsection (a), the Board of Pharmacy shall make findings with respect to the substance under consideration.
If it finds that any 1 substance not already controlled under any schedule has a potential for abuse, it shall recommend to the Legislature that the substance be added to the appropriate schedule.
If it finds that any substance already controlled under any schedule should be rescheduled or deleted, it shall so recommend to the Legislature.
(c) If the Board of Pharmacy designates a substance as an immediate precursor, substances which are precursors of the controlled precursor shall not be subject to control solely because they are precursors of the controlled precursor.
(d) If any substance is designated, rescheduled or deleted as a controlled substance under federal laws and notice thereof is given to the Board of Pharmacy, the board shall recommend similar control of such substance to the Legislature, specifically stating that such recommendation is based on federal action and the reasons why the federal government deemed such action necessary and proper.
(e) The authority vested in the board by subsection (a) of this section shall not extend to distilled spirits, wine, malt beverages or tobacco as those terms are defined or used in other chapters of this code nor to any nonnarcotic substance if such substance may under the “Federal Food, Drug and Cosmetic Act” and the law of this state lawfully be sold over the counter without a prescription.
(f) Notwithstanding any provision of this chapter to the contrary, the sale, wholesale, distribution or prescribing of a cannabidiol or nabiximols in a product approved by the Food and Drug Administration is permitted and shall be placed on the schedule or descheduled as provided for by the Drug Enforcement Administration.
(g) Notwithstanding §60A-2-204(d) of this code, if a organic psilocybin substance or drug that contains the pharmaceutical composition of crystalline polymorph psilocybin is approved by the United States Food and Drug Administration and rescheduled by the United States Drug Enforcement Administration it shall be lawful to prescribe, distribute, and market based upon the recommendations of the United States Food and Drug Administration.
2 §60A-2-204.
Intr HB 2026R1161 Betacetylmethadol;
Betacetylmethadol;
Betamethadol;
3 Betamethadol;
Intr HB 2026R1161 Furethidine;
Furethidine;
3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4-piperidinyl]-phenylpropanamide);
4 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4-piperidinyl]-phenylpropanamide);
Intr HB 2026R1161 Racemoramide;
Racemoramide;
Benzylmorphine;
5 Benzylmorphine;
Intr HB 2026R1161 Pholcodine;
Pholcodine;
Alpha-ethyltryptamine;
7-hydroxymitragynine’ means the naturally occurring or synthetically derived alkaloid of Mitragyna speciosa, including any salt, isomer, metabolite, analog, derivative, or synthetic equivalent.
‘Synthetic kratom alkaloid’ means any chemically modified, concentrated, isolated, or 6 artificially enhanced alkaloid derived from Mitragyna speciosa that exhibits opioid receptor activity Alpha-ethyltryptamine;
Intr HB 2026R1161 3,4-methylenedioxymethamphetamine (MDMA);
3,4-methylenedioxymethamphetamine (MDMA);
3,4-methylenedioxy-N-ethylamphetamine (also known as ( ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
3,4-methylenedioxy-N-ethylamphetamine (also known as ( ethyl-alpha-methyl-3,4 7 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
Intr HB 2026R1161 N-methyl-3-piperidyl benzilate;
N-methyl-3-piperidyl benzilate;
Psilocyn;
except as provided for in §60A-2-201(g) of this code;
8 Psilocyn;
Show all 500 changed rows (460 more)
Previous
Latest
Intr HB 2026R1161 1[1-(2-thienyl)cyclohexyl]pyrroldine;
1[1-(2-thienyl)cyclohexyl]pyrroldine;
3,4-methylenedioxypyrovalerone (MDPV);
9 3,4-methylenedioxypyrovalerone (MDPV);
[(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a- tetrahydrobenzo[c]chromen-1-ol)] { also known as HU-210} ;
[(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol)] { also known as HU-210} ;
Intr HB 2026R1161 (dexanabinol);
(dexanabinol);
(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzol[c]chromen-1-ol) { also known as HU-211} ;
(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 10 tetrahydrobenzol[c]chromen-1-ol) { also known as HU-211} ;
Intr HB 2026R1161 HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2- YL)-6A,7,10,10atetrahydrobenzo[ C]chromen-1-OL);
HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2- YL)-6A,7,10,10atetrahydrobenzo[ C]chromen-1-OL);
JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
11 JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
Intr HB 2026R1161 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C- NBOMe);
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C- NBOMe);
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B- NBOMe);
12 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B- NBOMe);
Intr HB 2026R1161 2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (etodesnitazene);
2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (etodesnitazene);
N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (flunitazene);
N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine 13 (flunitazene);
2-(4-ethoxybenzyl)5-nitro-1-(2-(pyrrolidin-1-yl)ethyH-benzimidazole (N-pyrrolidino etonitazene, etonitazepyne);
2-(4-ethoxybenzyl)5-nitro-1-(2-(pyrrolidin-1-ylH-benzimidazole (N-pyrrolidino etonitazene, etonitazepyne);
Intr HB 2026R1161 JWH 015;
JWH 015;
JWH 019;
14 JWH 019;
This shall include Intr HB 2026R1161 the following:
This shall include the following:
JWH 250;
15 JWH 250;
Adamantoylindoles or any compound containing a 3-(-1-Adamantoyl) indole structure with Intr HB 2026R1161 substitution at the nitrogen atom of the indole ring whether or not further substituted in the adamantoyl ring system to any extent.
Adamantoylindoles or any compound containing a 3-(-1-Adamantoyl) indole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the adamantoyl ring system to any extent.
Tetramethylcyclopropylindoles or any compound containing A 3- tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent.
16 Tetramethylcyclopropylindoles or any compound containing A 3- tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent.
Intr HB 2026R1161 5-Fluoro-MN-24 (1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide);
5-Fluoro-MN-24 (1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide);
SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
17 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4- Intr HB 2026R1161 benzodiazepin-2-one);
Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4- benzodiazepin-2-one);
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepine);
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-[1,2,4]triazolo[4,3- 18 a][1,4]diazepine);
Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3 Intr HB 2026R1161 a][1,4]benzodiazepine);
Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3 a][1,4]benzodiazepine);
Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4- benzodiazepin-2-one);
Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4- 19 benzodiazepin-2-one);
Intr HB 2026R1161 4,4'-Dimethylaminorex (4,4′-DMAR;
4,4'-Dimethylaminorex (4,4′-DMAR;
Cathinone;
20 Cathinone;
Intr HB 2026R1161 2-Fluoromethamphetamine;
2-Fluoromethamphetamine;
4-Fluoromethamphetamine;
21 4-Fluoromethamphetamine;
N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanami(thenylfentanyl),its optical isomers, salts, and salts of isomers.
N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical isomers, salts, and salts of isomers.
3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N- Intr HB 2026R1161 phenylbutyramide);
3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N- phenylbutyramide);
4-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4- yl)butyramide);
4-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4- 22 yl)butyramide);
§60A-2-204.
23
Schedule I.
1 (a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section including their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.
(b) Opiates.
Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl) -4-piperidinyl]— phenylacetamide);
Acetylmethadol;
Allylprodine;
Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha- acetylmethadol, levomethadyl acetate, or LAAM);
Alphameprodine;
Alphamethadol;
Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide;
1-(1-methyl-2-phenylethyl)-4-(( propanilido) piperidine);
Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl-4-piperidinyl]— phenylpropanamide);
Benzethidine;
Betacetylmethadol;
Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide);
Beta-hydroxy-3-methylfentanyl (other name:
N-[1-(2- hydroxy-2-phenethyl)-3-methyl-4- piperidinyl]-N-phenylpropanamide);
Betameprodine;
Betamethadol;
Intr HB 2026R1161 Betaprodine;
Clonitazene;
Dextromoramide;
Diampromide;
Diethylthiambutene;
Difenoxin;
Dimenoxadol;
Dimepheptanol;
Dimethylthiambutene;
Dioxaphetyl butyrate;
Dipipanone;
Ethylmethylthiambutene;
Etonitazene;
Etoxeridine;
Furethidine;
Hydroxypethidine;
Ketobemidone;
Levomoramide;
Levophenacylmorphan;
3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4- piperidyl]-N-phenylpropanamide);
3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4- piperidinyl]—phenylpropanamide);
Morpheridine;
N-Methylnorfentanyl (N-(1-Methyl-4-piperidinyl)-N-phenyl-propanamide, monohydrochloride);
Norfentanyl (N-Phenyl-N-4-piperidinyl-propanamide);
MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
Intr HB 2026R1161 Noracymethadol;
Norlevorphanol;
Normethadone;
Norpipanone;
Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- phenethyl)-4-piperidinyl] propanamide);
PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
Phenadoxone;
Phenampromide;
Phenomorphan;
Phenoperidine;
Piritramide;
Proheptazine;
Properidine;
Propiram;
Racemoramide;
Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]-propanamide);
Tilidine;
Trimeperidine.
(c) Opium derivatives, Acetorphine;
Acetyldihydrocodeine;
Benzylmorphine;
Codeine methylbromide;
Codeine-N-Oxide;
Cyprenorphine;
Desomorphine;
Intr HB 2026R1161 Dihydromorphine;
Drotebanol;
Etorphine (except HCl Salt);
Heroin;
Hydromorphinol;
Methyldesorphine;
Methyldihydromorphine;
Morphine methylbromide;
Morphine methylsulfonate;
Morphine-N-Oxide;
Myrophine;
Nicocodeine;
Nicomorphine;
Normorphine;
Pholcodine;
Thebacon.
(d) Hallucinogenic substances.
Alpha-ethyltryptamine;
some trade or other names:
etryptamine;
Monase;
alpha-ethy-1H- indole-3-ethanamine;
3-(2- aminobutyl) indole;
alpha-ET;
and AET;
4-bromo-2, 5-dimethoxy-amphetamine;
some trade or other names:
4-bromo-2,5- dimethoxy-alpha-methylphenethylamine;
4-bromo- 2,5-DMA;
4-Bromo-2,5-dimethoxyphenethylamine;
some trade or other names:
2-(4-bromo-2,5- dimethoxyphenyl)-1-aminoethane;
alpha- desmethyl DOB;
2C-B, Nexus;
N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine.
The substance has the acronym 25B-NBOMe;
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe);
Intr HB 2026R1161 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe);
2,5-dimethoxyamphetamine;
some trade or other names:
2,5-dimethoxy-alpha- methylphenethylamine;
2,5-DMA;
2,5-dimethoxy-4-ethylamphet-amine;
some trade or other names:
DOET;
2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name:
2C-T-7);
4-methoxyamphetamine;
some trade or other names:
4-methoxy-alpha- methylphenethylamine;
paramethoxyamphetamine;
PMA;
3-Hydoxy-phencyclidine (other name hydroxy PCP);
5-methoxy-3, 4-methylenedioxy-amphetamine;
4-methyl-2,5-dimethoxy-amphetamine;
some trade and other names:
4-methyl-2,5- dimethoxy-alpha-methylphenethylamine;
"DOM";
and "STP";
3,4-methylenedioxy amphetamine;
3,4-methylenedioxymethamphetamine (MDMA);
3,4-methylenedioxy-N-ethylamphetamine (also known as ( ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
N-hydroxy-3,4-methylenedioxyamphetamine (also known as ( hydroxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and ( hydroxy MDA);
3,4,5-trimethoxy amphetamine;
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
Alpha-methyltryptamine (other name:
AMT);
Bufotenine;
some trade and other names:
3-(beta-Dimethylaminoethyl)-5- hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol;
N, N-dimethylserotonin;
5-hydroxy-N,N- dimethyltryptamine;
mappine;
Diethyltryptamine;
sometrade and other names:
N, N-Diethyltryptamine;
DET;
Dimethyltryptamine;
some trade or other names:
DMT;
5-Methoxy-N,N-disopropyltryptamine (5-MeO-DIPT);
Intr HB 2026R1161 Ibogaine;
some trade and other names:
7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro-2- methoxy-6, 9-methano-5H- pyrido [1’, 2’:
1, 2] azepino [5,4-b] indole;
Tabernanthe iboga;
Lysergic acid diethylamide;
Marihuana;
Marijuana (Cannabis, sp.);
Mescaline;
Parahexyl-7374;
some trade or other names:
3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b,d] pyran;
Synhexyl;
Peyote;
meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, immediate derivative, mixture, or preparation of such plant, its seeds or extracts;
N-ethyl-3-piperidyl benzilate;
N-methyl-3-piperidyl benzilate;
Psilocybin;
Psilocyn;
Tetrahydrocannabinols;
synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp.
and/or synthetic substances, immediate derivatives and their isomers with similar chemical structure and pharmacological activity including, but not limited to the following:
delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;
delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;
delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;
delta-8 Cis or trans tetrahydrocannabinol and its optical isomers;
and delta-10 Cis or trans tetrahydrocannabinol and its optical isomers;
(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.) Intr HB 2026R1161 Delta-8-tetrahydrocannabinol-O (delta-8-THC-0), Delta-9-tetrahydrocannabinol (delta-9- THC-0) and Synthetic and non-naturally occurring cannabinoids.
The provisions of this section related to tetrahydrocannabinols are inapplicable to products or substances lawfully manufactured, distributed, or possessed under the provisions of §19-12E- 1 et seq.
and Chapter 16H of this code.
Ethylamine analog of phencyclidine;
some trade or other names:
N-ethyl-1- phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
Pyrrolidine analog of phencyclidine;
some trade or other names:
1-(1-phenylcyclohexyl)- pyrrolidine, PCPy, PHP;
Thiophene analog of phencyclidine;
some trade or other names:
1-[1-(2-thienyl)- cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine;
TPCP, TCP;
1[1-(2-thienyl)cyclohexyl]pyrroldine;
some other names:
TCPy;
4-methylmethcathinone (Mephedrone);
3,4-methylenedioxypyrovalerone (MDPV);
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
3,4-Methylenedioxy-N-methylcathinone (Methylone);
2,5-dimethoxy-4-(n)-propyltghiophenethylamine (2C-T-7, itsoptical isomers, salts and Intr HB 2026R1161 salts of isomers;
5-methoxy-N,N-dimethyltryptamine some trade or other names:
5-methoxy-3-[2- (dimethylamino)ethyl]indole;
5-MeO-DMT(5-MeO-DMT);
Alpha-methyltryptamine (other name:
AMT);
5-methoxy-N,N-diisopropyltryptamine (other name:
5-MeO-DIPT);
Synthetic Cannabinoids as follows:
2-[(1R,3S)-3-hydroxycyclohexyl]-5- (2-methyloctan-2-yl)phenol) {also known as CP 47,497 and homologues};
rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol {also known as CP 47,497-C8 homolog};
[(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a- tetrahydrobenzo[c]chromen-1-ol)] {also known as HU-210};
(dexanabinol);
(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzol[c]chromen-1-ol) {also known as HU-211};
1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-018};
1-Butyl-3-(1-naphthoyl)indole {also known as JWH-073};
(2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-methanone {also known as JWH-015};
(1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-019};
[1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone {also known as JWH-200};
1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone {also known as JWH-250};
2-((1S,2S,5S)-5-hydroxy-2- (3-hydroxtpropyl)cyclohexyl) -5-(2-methyloctan-2-yl)phenol {also known as CP 55,940};
(4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-122};
(4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-398;
Intr HB 2026R1161 (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone {also known as RCS-4};
1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone {also known as RCS-8};
1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
and 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
Synthetic cannabinoids:
CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2- YL)phenol);
HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10, 10A-tetrahydrobenzo[C] chromen-1-OL)];
HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2- YL)-6A,7,10,10atetrahydrobenzo[ C]chromen-1-OL);
JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
JWH-019, 1-hexyl-3-(1-naphthoyl)indole;
JWH-073, 1-butyl-3-(1-naphthoyl)indole;
JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.] Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbuta(5F-e ADB);
Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutano(FUB- AMB);
N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA);
Intr HB 2026R1161 Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA);
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB- FUBINACA);
Tetrahydrocannabinols:
DELTA-1 CIS OR trans tetrahydrocannabinol and their Optical isomers.
DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.
DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
Synthetic Phenethylamines 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanam(25I-NBOMe/ 2C-I- NBOMe);
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C- NBOMe);
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B- NBOMe);
Synthetic Opioids (including their isomers, esters, ethers, salts and salts of isomers, esters and ethers):
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
furanyl fentanyl;
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U- 47700);
N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramidalso known as N-(1- phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);
N-[1-[2-hydroxy-2-(thiophen-2-yl)ethylpiperidin-4-yl]-N-phenylpropionamide, also known as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanam(beta- hydroxythiofentanyl);
Intr HB 2026R1161 N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl);
N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl);
2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide (also known as U-48800);
Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as U-49900);
Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide (also known as U-51754);
2-(2-( 4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (butonitazene);
2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (etodesnitazene);
N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (flunitazene);
N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine (metodesnitazene);
N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (metonitaze);
2-(4-ethoxybenzyl)5-nitro-1-(2-(pyrrolidin-1-yl)ethylH-benzimidazole (N- pyrrolidino etoitazene, etonitazepyne);
N,N-diethyl-2-(5-nitro-2-(4- propoxybenzyl)-1H-benzimidazol-1- yl)ethan-1-amine (protonitazene);
N-pyrrolidino etonitazene;
Etodesnitazene;
Isotonitazene;
Intr HB 2026R1161 Protonitazene;
Metonitazene;
Butonitazene;
Metodesnitazene;
Flunitazene;
Opioid Receptor Agonist AH-7921 (3,4-dichloro-N- (1dimethylamino)cyclohexylmethyl]benzamide).
Naphthoylindoles or any compound containing a 3-(-1- Napthoyl) indole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
This shall include the following:
JWH 015;
JWH 018;
JWH 019;
JWH 073;
JWH 081;
JWH 122;
JWH 200;
JWH 210;
JWH 398;
AM 2201;
and WIN 55,212.
Naphylmethylindoles or any compound containing a 1hindol-3-yl-(1-naphthyl) methane structure with a substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
This shall include, but not be limited to, JWH 175 and JWH 184.
Intr HB 2026R1161 Naphthoylpyrroles or any compound containing a 3-(1- Naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
This shall include, but not be limited to, JWH 147 and JWH 307.
Naphthylmethylindenes or any compound containing a Naphthylideneindene structure with substitution at the 3- Position of the indene ring whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
This shall include, but not be limited to, JWH 176.
Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
This shall include the following:
RCS-8, SR-18 OR BTM-8;
JWH 250;
JWH 203;
JWH 251;
and JWH 302.
Cyclohexylphenols or any compound containing a 2-(3- hydroxycyclohexyl) phenol structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the cyclohexyl ring to any extent.
This shall include the following:
CP 47,497 and its homologues and analogs;
Cannabicyclohexanol;
and CP 55,940.
Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogren atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
This shall include Intr HB 2026R1161 the following:
AM 694;
Pravadoline WIN 48,098;
RCS 4;
and AM 679.
[2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-YL]-1- napthalenymethanone.
This shall include WIN 55,212-2.
Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol structure with substitution on the 3-pentyl group.
This shall include HU-210, HU-211, JWH 051, and JWH 133.
Adamantoylindoles or any compound containing a 3-(-1- Adamantoyl) indole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the adamantoyl ring system to any extent.
This shall include AM1248.
Tetramethylcyclopropylindoles or any compound containing A 3- tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent.
This shall include UR-144 and XLR-11.
N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide.
This shall include AKB48.
Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV, and V, not federal Food and Drug Administration approved drug or used within legitimate, approved medical research.
Since nomenclature of these substances is not internationally standardized, any immediate precursor or immediate derivative of these substances shall be covered.
Tryptamines:
5- methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT);
4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
Intr HB 2026R1161 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT);
4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT);
5-methoxy-α-methyltryptamine (5-MeO-AMT);
4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT);
4-hydroxy Diethyltryptamine (4-HO-DET);
5- methoxy- N,N- diallyltryptamine (5-MeO-DALT);
4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT);
4-hydroxy Diethyltryptamine (4-HO-DET);
FDU-PB-22 (1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
FUB-PB-22 (Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
5-Fluoro-MN-24 (1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide);
MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
  SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
Methyl-Ethylaminopentiophenone;
FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3- carboxamide);
MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3- methylbutanoat);
MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
Intr HB 2026R1161  Methyl-Ethylaminopentiophenone;
 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole- 3- carboxamide);
 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3- methylbutanoat);
 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4- benzodiazepin-2-one);
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepine);
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);
Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3- a][1,4]diazepine);
Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2- one) ;
Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
and Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine).
Intr HB 2026R1161 (e) Depressants.
4-CN-CUMYL-BUTINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2- yl)-1H-indazole-3- carboxamide);
Alpha-Phenylacetoacetonitrile (3-Oxo-2-phenylbutanenitrile);
2-Fluoro Deschloroketamine (2-(2-Fluorophenyl)-2-(methylamino)-cyclohexanone, monohydrochloride);
4-MEAP (2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one);
Mecloqualone;
Methaqualone;
Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3 a][1,4]benzodiazepine);
Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4- benzodiazepin-2-one);
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepine);
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);
Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3- a][1,4]diazepine);
Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2- one);
Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
Intr HB 2026R1161 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Declazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2- one);
and Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3- a][1,4]diazepine);
(f) Stimulants.
Aminorex;
some other names:
aminoxaphen;
2-amino-5- phenyl-2-oxazoline;
or 4,5- dihydro-5-phenyl-2-oxazolamine;
Cathinone;
some trade or other names:
2-amino-1-phenyl-1- propanone, alpha- aminopropiophenone, 2-aminopropiophenone and norephedrone;
Fenethylline;
Methcathinone, its immediate precursors and immediate derivatives, its salts, optical isomers and salts of optical isomers;
some other names:
(2-(methylamino)-propiophenone;
alpha- (methylamino)propiophenone;
2-(methylamino)-1-phenylpropan-1- one;
alpha—- methylaminopropiophenone;
monomethylpropion;
3,4-methylenedioxypyrovalerone and/or mephedrone;3,4-methylenedioxypyrovalerone (MPVD);
ephedrone;
N-methylcathinone;
methylcathinone;
AL-464;
AL-422;
AL- 463 and UR1432;
(+-) cis-4-methylaminorex;
((+-)cis-4,5-dihydro-4-methyl- 5-phenyl-2-oxazolamine);
N-ethylamphetamine;
N,N-dimethylamphetemine;
also known as N,N-alpha- trimethyl-benzeneethanamine;
N,N-alpha-trimethylphenethylamine;
Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and salts of isomers;
Substituted amphetamines:
2-Fluoroamphetamine;
View plain text versions (2)

Action History

  1. Filed for introduction

  2. To Health and Human Resources

  3. Introduced in House

  4. To House Health and Human Resources

  5. Markup Discussion

  6. By substitute, do pass

  7. On 1st reading, Special Calendar

  8. Postponed on 1st reading, Special Calendar, until January 30, 2026

  9. Placed on House Calendar

  10. On 1st reading, House Calendar

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 1 co-sponsors · 150 not signed on

Sponsors (1)

Co-sponsors (1)

Not signed on (150)

150 members have not signed on to this bill.

Show all 150 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 4640 do?
Relating to drugs and adding a provision relating to the scheduling of crystalline polymorph psilocybin approved by the Food and Drug Administration
Who sponsors HB 4640?
HB 4640 is sponsored by Evan Worrell (Republican) and Michael Hite (Republican).
What is the current status of HB 4640?
This bill died with 2026 Session. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 4640?
Track HB 4640 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 4640

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of HB 4640

Last checked for changes about 1 month ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →